Interní Med. 2006; 8(1): 42-43

Epidemiologie a klasifikace chronického onemocnění ledvin

prof. MUDr. Vladimír Tesař DrSc
Klinika nefrologie 1. LF UK a VFN, Praha

Klasifikace chronického onemocnění ledvin – Chronická renální insuficience je podstatně častější než chronické selhání ledvin. Zatímco pacientů s terminálním selháním ledvin léčených některou z metod náhrady funkce ledvin je v populaci méně než 0,1 %, údaje z americké studie NHANES III (K/DOQI Guidelines, 2002, Coresh et al., 2003) ukazují, že v obecné populaci je cca 0,2 % pacientů s glomerulární filtrací 15–29 ml/min/1,73 m2 tělesného povrchu a cca 4,3 % pacientů s glomerulární filtrací 30–59 ml/min/1,73 m2. Výskyt střední a těžké renální insuficience stoupá v populaci výrazně s věkem. Zatímco ve věku 20–39 let má glomerulární filtraci nižší než 1,2 ml/s jen 6,3 % populace, ve věkové skupině 60–79 let je to již 65 %. Je pravděpodobné, že s progresí chronické renální insuficience stoupá i kardiovaskulární riziko a riziko dalších komplikací chronické renální insuficience. Až donedávna však neexistovala žádná všeobecně akceptovaná klasifikace chronické renální insuficience...

Published: March 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Tesař V. Epidemiologie a klasifikace chronického onemocnění ledvin. Interní Med. 2006;8(1):42-43.
Download citation

References

  1. Asselbergs FW, Diercks GF, Hillege HL, et al. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation, 2004; 110: 2809-2816. Go to original source... Go to PubMed...
  2. Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am. J. Kidney Dis., 2003; 41: 1-12. Go to original source... Go to PubMed...
  3. de Leeuw PW, Thijs L, Birkenhager WH, et al. Prognostic significance of renal function in elderly patients with isolated systolic hypertension: results from the Syst-Eur trial. J. Am. Soc. Nephrol., 2002; 13: 2213-2222. Go to original source... Go to PubMed...
  4. Executive Summary of the Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA, 2001; 285: 2486-2497. Go to original source... Go to PubMed...
  5. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA, 2002; 287: 356-359. Go to original source... Go to PubMed...
  6. Geluk CA, Asselbergs FW, Hillege HL, et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur. Heart J., 2005; 26: 1314-1320. Go to original source... Go to PubMed...
  7. Henry RMA, Kostense PJ, Bos G, et al. Mild renal insufficiency is associated with increased cardiovascular mortality: The Hoorn Study. Kidney Int., 2002; 62: 1402-1407. Go to original source... Go to PubMed...
  8. Hillege HL, Janssen WM, Bak AA, et al. Microalbuminuria is common, also in nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J. Intern. Med., 2001; 249: 519-526. Go to original source... Go to PubMed...
  9. K/DOQI Clinical Practice Guidelines for Chronic Kidney Disease: evaluation, classification, and stratification. Am. J. Kidney Dis., 2002; 39 (Suppl. 1): S1-S266.
  10. Kurella M, Lo JC, Chertow GM. Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J. Am. Soc. Nephrol., 2005; 16: 2134-2140. Go to original source... Go to PubMed...
  11. Levey AS, Beto JA, Coronado BE, et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? Am. J. Kidney Dis., 1998; 32: 853-906. Go to original source... Go to PubMed...
  12. Mann JFE, Gerstein HC, Pogue J, et al. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann. Intern. Med., 2001; 134: 629-636. Go to original source... Go to PubMed...
  13. Ohmit SE, Flack JM, Peters RM, et al. Longitudinal study of the National Kidney Foundations (NKF) Kidney Early Evaluation Program (KEEP). J. Am. Soc. Nephrol., 2003; 14 (Suppl. 2): S117-121. Go to original source... Go to PubMed...
  14. Ruilope LM, Salvetti A, Jamerson K, et al. Renal function and intensive lowering of blood pressure in hypertensive participants of the Hypertension Optimal Treatment (HOT) Study. J. Am. Soc. Nephrol., 2001; 12: 218-225. Go to original source... Go to PubMed...




Internal Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.